The Alliance for Children's Therapeutics (ACT) was formed to develop better medications for children and teens with autoimmune diseases like lupus, multiple sclerosis and juvenile arthritis - faster than ever before.
ACT unites one of the nation's top-five pediatric research institutions - Seattle Children's Research Institute - with Kineta, Inc., a leading biotechnology firm.
To learn more, visit:
Seattle Children's Research Institute: http://www.seattlechildrens.org/research/
Kineta, Inc.: http://www.kinetabio.com/